CN105829315B - 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类 - Google Patents

可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类 Download PDF

Info

Publication number
CN105829315B
CN105829315B CN201480069437.9A CN201480069437A CN105829315B CN 105829315 B CN105829315 B CN 105829315B CN 201480069437 A CN201480069437 A CN 201480069437A CN 105829315 B CN105829315 B CN 105829315B
Authority
CN
China
Prior art keywords
mmol
methyl
dichlorophenyl
amino
dihydropyrimido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480069437.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105829315A (zh
Inventor
蒂莫西·哈里森
格雷厄姆·特雷维特
彼得·罗宾·休伊特
科林·罗德里克·奥多德
弗兰克·布尔坎普
安德鲁·约翰·威尔金森
史蒂文·D·谢泼德
休斯·米尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Discovery Ltd
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of CN105829315A publication Critical patent/CN105829315A/zh
Application granted granted Critical
Publication of CN105829315B publication Critical patent/CN105829315B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480069437.9A 2013-12-19 2014-12-19 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类 Active CN105829315B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1322602.2 2013-12-19
GBGB1322602.2A GB201322602D0 (en) 2013-12-19 2013-12-19 Pharmaceutical compounds
PCT/GB2014/053793 WO2015092431A1 (en) 2013-12-19 2014-12-19 Pyrimidopyrimidinones useful as wee-1 kinase inhibitors

Publications (2)

Publication Number Publication Date
CN105829315A CN105829315A (zh) 2016-08-03
CN105829315B true CN105829315B (zh) 2019-03-08

Family

ID=50071157

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480069437.9A Active CN105829315B (zh) 2013-12-19 2014-12-19 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类

Country Status (28)

Country Link
US (1) US9850247B2 (enExample)
EP (1) EP3083625B1 (enExample)
JP (1) JP6437559B2 (enExample)
KR (1) KR102405462B1 (enExample)
CN (1) CN105829315B (enExample)
AU (1) AU2014369457B2 (enExample)
BR (1) BR112016014151B1 (enExample)
CA (1) CA2933755C (enExample)
CY (1) CY1120035T1 (enExample)
DK (1) DK3083625T3 (enExample)
ES (1) ES2650013T3 (enExample)
GB (1) GB201322602D0 (enExample)
HR (1) HRP20180080T1 (enExample)
HU (1) HUE037908T2 (enExample)
IL (1) IL245672B (enExample)
LT (1) LT3083625T (enExample)
MX (1) MX371108B (enExample)
NO (1) NO3083625T3 (enExample)
NZ (1) NZ720178A (enExample)
PL (1) PL3083625T3 (enExample)
PT (1) PT3083625T (enExample)
RS (1) RS56731B1 (enExample)
RU (1) RU2691105C1 (enExample)
SG (1) SG11201603814TA (enExample)
SI (1) SI3083625T1 (enExample)
SM (1) SMT201800020T1 (enExample)
WO (1) WO2015092431A1 (enExample)
ZA (1) ZA201603337B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137593B (zh) * 2015-04-21 2021-01-05 上海交通大学医学院附属瑞金医院 蛋白激酶抑制剂的制备和用途
US10947238B2 (en) 2015-11-01 2021-03-16 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of making and using the same
EP3543242B1 (en) * 2016-11-16 2024-01-03 Impact Therapeutics (Shanghai), Inc 8,9-dihydroimidazole[1,2-a]pyrimido[5,4-e]pyrimidine-5(6h)-ketone compound
EP3564232B1 (en) 2016-12-27 2022-01-26 Riken Bmp-signal-inhibiting compound
WO2018133829A1 (zh) 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
GB201703881D0 (en) 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
CA3058457A1 (en) 2017-03-31 2018-10-04 Seattle Genetics, Inc. Combinations of chk1- and wee1 - inhibitors
CN110914277B (zh) * 2017-07-10 2022-08-09 上海瑛派药业有限公司 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CA3078945A1 (en) 2017-10-09 2019-04-18 Nuvation Bo Inc. Heterocyclic compounds and uses thereof
EP3694861A4 (en) 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
PL3712150T3 (pl) 2017-11-01 2024-09-02 Wuxi Biocity Biopharmaceutics Co., Ltd. Związek makrocykliczny służący jako inhibitor wee1 i jego zastosowania
AU2019227823B2 (en) * 2018-02-28 2024-12-12 The Regents Of The University Of Colorado, A Body Corporate WEE1 kinase inhibitors and methods of treating cancer using the same
CN112771049B (zh) * 2018-09-27 2024-01-26 贝达药业股份有限公司 Fgfr4抑制剂及其应用
CN112955454A (zh) 2018-10-26 2021-06-11 石家庄智康弘仁新药开发有限公司 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
US20230065740A1 (en) 2018-12-28 2023-03-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
KR102697799B1 (ko) 2019-03-22 2024-08-23 쇼우야오 홀딩스 (베이징) 코., 엘티디. Wee1 억제제 및 이의 제조 및 용도
WO2020210383A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210377A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
AU2020271837A1 (en) 2019-04-09 2021-11-18 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
AU2020266956B2 (en) 2019-04-30 2025-05-08 Wuxi Biocity Biopharmaceutics Co., Ltd. Crystal form of Wee1 inhibitor compound and use thereof
CN112142763B (zh) * 2019-06-28 2024-01-26 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CA3180664A1 (en) 2020-06-17 2021-12-23 Yuli Xie Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor
EP4221710A4 (en) * 2020-10-01 2024-09-18 University of Washington DRUG-LIKE MOLECULES AND METHODS FOR THERAPEUTIC TARGETING OF MICRORNA-21
MX2023007244A (es) * 2020-12-18 2023-06-29 Glaxosmithkline Ip Dev Ltd Compuestos quimicos utiles para inhibir los canales de sodio activados por voltaje de nav1.8 y tratar las enfermedades mediadas por nav1.8.
EP4263540A1 (en) * 2020-12-18 2023-10-25 GlaxoSmithKline Intellectual Property Development Limited Nitrogen containing 2,3-dihydroquinazolinone compounds as nav1.8 inhibitors
US20240182482A1 (en) 2021-04-30 2024-06-06 Wigen Biomedicine Technology (shanghai) Co., Ltd. Fused cyclic compound as wee-1 inhibitor, preparation method therefor and use thereof
BR112023025403A2 (pt) 2021-06-25 2024-02-20 Korea Res Inst Chemical Tech Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo
CN116462687B (zh) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
WO2023217201A2 (zh) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
WO2025101691A1 (en) 2023-11-08 2025-05-15 Exelixis, Inc. Methods for treating cancer using compounds that inhibit pkmyt1

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085167A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
CN102816164A (zh) * 2012-08-31 2012-12-12 北京理工大学 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法
WO2013013031A1 (en) * 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
WO2013059485A1 (en) * 2011-10-20 2013-04-25 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2005090344A1 (en) 2004-03-15 2005-09-29 F. Hoffmann-La Roche Ag Novel dichloro-phenyl-pyrido [2,3-d] pyrimidine derivates, their manufacture and use as pharmaceutical agents
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
WO2008133866A1 (en) 2007-04-25 2008-11-06 Merck & Co., Inc. Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor
US8436004B2 (en) 2007-06-15 2013-05-07 Msd K.K. Bicycloaniline derivative
US8329711B2 (en) 2007-10-23 2012-12-11 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
WO2010067886A1 (en) 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivative
AU2009325400A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
CN103347864B (zh) * 2010-12-06 2016-08-10 葛兰素集团有限公司 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
TWI532742B (zh) * 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
EP2731953A1 (en) 2011-07-15 2014-05-21 Abbvie Inc. Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085167A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
WO2013013031A1 (en) * 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
WO2013059485A1 (en) * 2011-10-20 2013-04-25 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
CN102816164A (zh) * 2012-08-31 2012-12-12 北京理工大学 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法

Also Published As

Publication number Publication date
DK3083625T3 (en) 2017-12-18
US20160318936A1 (en) 2016-11-03
GB201322602D0 (en) 2014-02-05
SG11201603814TA (en) 2016-07-28
AU2014369457A1 (en) 2016-06-09
EP3083625A1 (en) 2016-10-26
BR112016014151B1 (pt) 2023-01-17
JP2017500335A (ja) 2017-01-05
CA2933755C (en) 2023-01-31
NZ720178A (en) 2022-05-27
WO2015092431A1 (en) 2015-06-25
KR20160098499A (ko) 2016-08-18
CA2933755A1 (en) 2015-06-25
MX371108B (es) 2020-01-17
ES2650013T3 (es) 2018-01-16
KR102405462B1 (ko) 2022-06-03
RU2691105C1 (ru) 2019-06-11
US9850247B2 (en) 2017-12-26
CY1120035T1 (el) 2018-12-12
PL3083625T3 (pl) 2018-03-30
MX2016007801A (es) 2016-09-07
SI3083625T1 (en) 2018-03-30
LT3083625T (lt) 2017-12-27
NO3083625T3 (enExample) 2018-03-31
IL245672B (en) 2021-10-31
CN105829315A (zh) 2016-08-03
PT3083625T (pt) 2018-02-06
RU2016123363A (ru) 2018-01-25
SMT201800020T1 (it) 2018-05-02
IL245672A0 (en) 2016-06-30
HRP20180080T1 (hr) 2018-03-09
AU2014369457B2 (en) 2018-08-09
RS56731B1 (sr) 2018-03-30
EP3083625B1 (en) 2017-11-01
HUE037908T2 (hu) 2018-09-28
BR112016014151A2 (enExample) 2017-08-08
JP6437559B2 (ja) 2018-12-12
ZA201603337B (en) 2018-07-25

Similar Documents

Publication Publication Date Title
CN105829315B (zh) 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类
CN102548557B (zh) 用于降低β-淀粉状蛋白生成的化合物
JP7073359B2 (ja) ユビキチン特異的プロテアーゼ７の阻害剤としてのピペリジン誘導体
CN104470925B (zh) 作为激酶抑制剂的咪唑并三嗪甲腈
CN107253963B (zh) 吡啶酮和氮杂吡啶酮化合物及使用方法
CN103339134B (zh) 三环吡咯并衍生物、它们的制备方法和它们作为激酶抑制剂的应用
CN105209463B (zh) 2‑氨基吡啶并[4,3‑d]嘧啶‑5‑酮衍生物及其作为Wee‑1抑制剂的用途
TWI624467B (zh) 選擇性經取代之喹啉化合物
CN102388055B (zh) 咪唑并[2,1-b][1,3,4]噻二唑衍生物
AU2009325398A1 (en) Dihydropyrimidopyrimidine derivative
WO2005118588A1 (ja) 縮合複素環化合物
WO2020156437A1 (zh) Akt抑制剂
CN115485276B (zh) 氘代akt激酶抑制剂
HK40050826B (zh) Akt抑制剂
HK1227877A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
HK1227877B (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
HK1201268B (zh) 二环哌嗪化合物
HK1223089A1 (zh) 激酶抑制剂及其用途
HK1201268A1 (en) Bicyclic piperazine compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant